The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi ...

As the science behind a novel approach to treating disease evolves, the focus of research and clinical development is expanding from rare conditions to far more common diseases.

Roche (USOTC:RHHBY) has secured exclusive worldwide rights to Rona Therapeutics’ investigational ALK7-targeting RNA ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference (RNAi) therapies headed by a ...

City Therapeutics (CTY), a developer of a novel treatment class known as RNA interference therapies, added more than 20% on ...

RNA interference (RNAi) acts like a "gene switch," selectively silencing specific genes. It uses specialized RNA molecules, such as small interfering RNA (siRNA) or microRNA (miRNA), to block genetic ...

RNA interference is a natural mechanism for living cells to control whether specific genes are being used or not. Crowned with the 2006 Nobel Prize for Physiology and Medicine, the discovery of RNA ...

Engineered human AGO2 and a C-to-U deaminase produced average messenger RNA editing 1.9-fold higher than two Cas13 ...